We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: JAK inhibitors
MedXY News
EnglishTag

JAK inhibitors

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Exploring Janus Kinase Inhibition as a Novel Therapeutic Avenue in Idiopathic Subglottic Stenosis
newsAirway DiseaseFibroinflammation

Exploring Janus Kinase Inhibition as a Novel Therapeutic Avenue in Idiopathic Subglottic Stenosis

By MedXY|Aug 28, 2026

JAK inhibitors, proven in rheumatoid arthritis, show potential in extending surgical-free intervals and reducing dilation frequency in idiopathic subglottic stenosis by targeting immune-mediated fibroinflammation.

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Evidence from Two Phase 3 UP-AA Randomized Clinical Trials
Allergy & ImmunologyJAK inhibitorsPhase 3 Clinical Trials
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Evidence from Two Phase 3 UP-AA Randomized Clinical Trials

By MedXY|Aug 17, 2026

Two large phase 3 trials demonstrated that upadacitinib significantly improves hair regrowth and quality of life in severe alopecia areata among adolescents and adults, with a consistent and manageable safety profile.

Long-term Efficacy and Safety of Upadacitinib in Alopecia Areata: A Comprehensive Review of Real-World Evidence and Translational Insights
Clinical Updatesreal‑world evidenceJAK inhibitors

Long-term Efficacy and Safety of Upadacitinib in Alopecia Areata: A Comprehensive Review of Real-World Evidence and Translational Insights

By MedXY|Aug 17, 2026

This review synthesizes current evidence on upadacitinib for alopecia areata, focusing on long-term efficacy, safety, and predictors of treatment response, highlighting the real-world retrospective study by Wang et al. alongside emerging cl

Feasibility and Comparative Outcomes of 24-Week Abrocitinib Tapering in Moderate-to-Severe Atopic Dermatitis
Allergy & ImmunologyAbrocitinibatopic dermatitis

Feasibility and Comparative Outcomes of 24-Week Abrocitinib Tapering in Moderate-to-Severe Atopic Dermatitis

By MedXY|Jul 12, 2026

This study evaluates the successful 24-week tapering of abrocitinib in moderate-to-severe atopic dermatitis patients, comparing dose reduction versus interval extension tapering regimens and demonstrating high feasibility with substantial d

Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment
Allergy & Immunologyatopic dermatitisdermatology

Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment

By MedXY|Mar 5, 2026

A Phase IIb clinical trial demonstrates that pumecitinib 3% gel significantly improves skin clearance in adults with mild-to-moderate atopic dermatitis. Twice-daily application proved superior to once-daily dosing, maintaining a favorable s

Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial
Allergy & Immunologyatopic dermatitisAzathioprine

Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial

By MedXY|Mar 5, 2026

A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both tre

Unorthodox JAK Inhibitor Dosing in Pediatric Moderate-to-Severe Alopecia Areata: A Comparative Evaluation of Tofacitinib and Baricitinib
Dermatologyalopecia areataBaricitinib

Unorthodox JAK Inhibitor Dosing in Pediatric Moderate-to-Severe Alopecia Areata: A Comparative Evaluation of Tofacitinib and Baricitinib

By MedXY|Mar 5, 2026

This study of 100 pediatric patients with moderate-to-severe alopecia areata demonstrates that unorthodox dosing regimens of tofacitinib and baricitinib provide comparable efficacy and high tolerability over 24 weeks.

Internal MedicineJAK inhibitorsmuscle wasting

Tofacitinib Reverses Muscle Loss in Rheumatoid Arthritis: Insights from the RAMUS Trial

By MedXY|Dec 19, 2025

The RAMUS study demonstrates that the JAK inhibitor tofacitinib significantly increases lower limb muscle volume in patients with rheumatoid arthritis, offering a potential explanation for associated creatinine elevations and a new therapeu

Internal MedicineJAK inhibitorsmuscle wasting

Tofacitinib and Muscle Volume: A Potential Paradigm Shift in Managing Rheumatoid Cachexia

By MedXY|Dec 19, 2025

The RAMUS study demonstrates that tofacitinib significantly increases lower limb muscle volume in rheumatoid arthritis patients, potentially explaining associated creatinine elevations and offering a new therapeutic avenue for combating mus

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities